nach oben

Erschienen in:

01.07.2020 | Original Article

Characterizing caspase-1 involvement during esophageal disease progression

verfasst von: Gillian Barber, Akanksha Anand, Katarzyna Oficjalska, James J. Phelan, Aisling B. Heeran, Ewelina Flis, Niamh E. Clarke, Jenny A. Watson, Julia Strangmann, Brian Flood, Hazel O’Neill, Dermot O’Toole, Finbar MacCarthy, Narayanasamy Ravi, John V. Reynolds, Elaine W. Kay, Michael Quante, Jacintha O’Sullivan, Emma M. Creagh

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Barrett’s esophagus (BE) is an inflammatory condition and a neoplastic precursor to esophageal adenocarcinoma (EAC). Inflammasome signaling, which contributes to acute and chronic inflammation, results in caspase-1 activation leading to the secretion of IL-1β and IL-18, and inflammatory cell death (pyroptosis). This study aimed to characterize caspase-1 expression, and its functional importance, during disease progression to BE and EAC. Three models of disease progression (Normal–BE–EAC) were employed to profile caspase-1 expression: (1) a human esophageal cell line model; (2) a murine model of BE; and (3) resected tissue from BE-associated EAC patients. BE patient biopsies and murine BE organoids were cultured ex vivo in the presence of a caspase-1 inhibitor, to determine the importance of caspase-1 for inflammatory cytokine and chemokine secretion.

Epithelial caspase-1 expression levels were significantly enhanced in BE (p < 0.01). In contrast, stromal caspase-1 levels correlated with histological inflammation scores during disease progression (p < 0.05). Elevated secretion of IL-1β from BE explanted tissue, compared to adjacent normal tissue (p < 0.01), confirmed enhanced activity of caspase-1 in BE tissue. Caspase-1 inhibition in LPS-stimulated murine BE organoids caused a significant reduction in IL-1β (p < 0.01) and CXCL1 (p < 0.05) secretion, confirming the importance of caspase-1 in the production of cytokines and chemokines associated with disease progression from BE to EAC. Targeting caspase-1 activity in BE patients should therefore be tested as a novel strategy to prevent inflammatory complications associated with disease progression.

Nur mit Berechtigung zugänglich

Quante M, Graham TA, Jansen M (2018) Insights into the pathophysiology of esophageal adenocarcinoma. Gastroenterology 154:406–420PubMed

Picardo SL, Maher SG, O'Sullivan JN, Reynolds JV (2012) Barrett’s to oesophageal cancer sequence: a model of inflammatory-driven upper gastrointestinal cancer. Dig Surg 29:251–260PubMed

Spechler SJ, Souza RF (2014) Barrett’s esophagus. N Engl J Med 371:836–845PubMed

Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P (2011) Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 365:1375–1383PubMed

Munch NS, Fang HY, Ingermann J, Maurer HC, Anand A, Kellner V, Sahm V, Wiethaler M, Baumeister T, Wein F, Einwachter H, Bolze F, Klingenspor M, Haller D, Kavanagh M, Lysaght J, Friedman R, Dannenberg AJ, Pollak M, Holt PR, Muthupalani S, Fox JG, Whary MT, Lee Y, Ren TY, Elliot R, Fitzgerald R, Steiger K, Schmid RM, Wang TC, Quante M (2019) High-fat diet accelerates carcinogenesis in a mouse model of Barrett’s esophagus via interleukin 8 and alterations to the gut microbiome. Gastroenterology 157:492–506.e492PubMedPubMedCentral

Creagh EM (2014) Caspase crosstalk: integration of apoptotic and innate immune signalling pathways. Trends Immunol 35:631–640PubMed

Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228–232PubMed

Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F, Shao F (2015) Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526:660–665PubMed

Karan D (2018) Inflammasomes: emerging central players in cancer immunology and immunotherapy. Front Immunol 9:3028–3028PubMedPubMedCentral

10.

Fitzgerald RC, Abdalla S, Onwuegbusi BA, Sirieix P, Saeed IT, Burnham WR, Farthing MJ (2002) Inflammatory gradient in Barrett’s oesophagus: implications for disease complications. Gut 51:316–322PubMedPubMedCentral

11.

Shrivastava MS, Hussain Z, Giricz O, Shenoy N, Polineni R, Maitra A, Verma A (2014) Targeting chemokine pathways in esophageal adenocarcinoma. Cell Cycle 13:3320–3327PubMedPubMedCentral

12.

Campos VJ, Mazzini GS, Juchem JF, Gurski RR (2020) Neutrophil-lymphocyte ratio as a marker of progression from non-dysplastic Barrett’s esophagus to esophageal adenocarcinoma: a cross-sectional retrospective study. J Gastrointest Surg 24:8–18PubMed

13.

Quante M, Bhagat G, Abrams JA, Marache F, Good P, Lee MD, Lee Y, Friedman R, Asfaha S, Dubeykovskaya Z, Mahmood U, Figueiredo JL, Kitajewski J, Shawber C, Lightdale CJ, Rustgi AK, Wang TC (2012) Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 21:36–51PubMedPubMedCentral

14.

Ponten F, Jirstrom K, Uhlen M (2008) The human protein atlas–a tool for pathology. J Pathol 216:387–393PubMed

15.

Nadatani Y, Huo X, Zhang X, Yu C, Cheng E, Zhang Q, Dunbar KB, Theiss A, Pham TH, Wang DH, Watanabe T, Fujiwara Y, Arakawa T, Spechler SJ, Souza RF (2016) NOD-like receptor protein 3 inflammasome priming and activation in Barrett’s epithelial cells. Cell Mol Gastroenterol Hepatol 2:439–453PubMedPubMedCentral

16.

Nakagawa H, Wang TC, Zukerberg L, Odze R, Togawa K, May GHW, Wilson J, Rustgi AK (1997) The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach. Oncogene 14:1185PubMed

17.

Fox JG, Beck P, Dangler CA, Whary MT, Wang TC, Shi HN, Nagler-Anderson C (2000) Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. Nat Med 6:536–542PubMed

18.

Schellnegger R, Quante A, Rospleszcz S, Schernhammer M, Höhl B, Tobiasch M, Pastula A, Brandtner A, Abrams JA, Strauch K, Schmid RM, Vieth M, Wang TC, Quante M (2017) Goblet-cell ratio in combination with differentiation and stem cell markers in Barrett’s esophagus allow distinction of patients with and without esophageal adenocarcinoma. Cancer Prevent Res (Philadelphia, Pa) 10:55–66

19.

Pastula A, Middelhoff M, Brandtner A, Tobiasch M, Hohl B, Nuber AH, Demir IE, Neupert S, Kollmann P, Mazzuoli-Weber G, Quante M (2016) Three-dimensional gastrointestinal organoid culture in combination with nerves or fibroblasts: a method to characterize the gastrointestinal stem cell niche. Stem Cells Int 2016:3710836PubMed

20.

Phelan JJ, MacCarthy F, Feighery R, O'Farrell NJ, Lynam-Lennon N, Doyle B, O'Toole D, Ravi N, Reynolds JV, O'Sullivan J (2014) Differential expression of mitochondrial energy metabolism profiles across the metaplasia-dysplasia-adenocarcinoma disease sequence in Barrett’s oesophagus. Cancer Lett 354:122–131PubMed

21.

Rano TA, Timkey T, Peterson EP, Rotonda J, Nicholson DW, Becker JW, Chapman KT, Thornberry NA (1997) A combinatorial approach for determining protease specificities: application to interleukin-1β converting enzyme (ICE). Chem Biol 4:149–155PubMed

22.

Benkova B, Lozanov V, Ivanov IP, Mitev V (2009) Evaluation of recombinant caspase specificity by competitive substrates. Anal Biochem 394:68–74PubMed

23.

Rozman-Pungercar J, Kopitar-Jerala N, Bogyo M, Turk D, Vasiljeva O, Stefe I, Vandenabeele P, Bromme D, Puizdar V, Fonovic M, Trstenjak-Prebanda M, Dolenc I, Turk V, Turk B (2003) Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity. Cell Death Differ 10:881–888PubMed

24.

Kavanagh ME, Conroy MJ, Clarke NE, Gilmartin NT, O'Sullivan KE, Feighery R, MacCarthy F, O'Toole D, Ravi N, Reynolds JV, O'Sullivan J, Lysaght J (2016) Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma. Cancer Lett 370:117–124PubMed

25.

di Pietro M, Lao-Sirieix P, Boyle S, Cassidy A, Castillo D, Saadi A, Eskeland R, Fitzgerald RC (2012) Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus. Proc Natl Acad Sci USA 109:9077–9082PubMed

26.

Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, Hart J, Smith KD, Mezhir JJ, Weichselbaum RR, Khodarev NN (2005) Progression of Barrett’s metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res 65:3146–3154PubMed

27.

Santana PT, Martel J, Lai H-C, Perfettini J-L, Kanellopoulos JM, Young JD, Coutinho-Silva R, Ojcius DM (2016) Is the inflammasome relevant for epithelial cell function? Microbes Infect 18:93–101PubMed

28.

Kopalli SR, Kang TB, Lee KH, Koppula S (2018) NLRP3 Inflammasome activation inhibitors in inflammation-associated cancer immunotherapy: an update on the recent patents. Recent Pat Anticancer Drug Discov 13:106–117PubMed

29.

Guo B, Fu S, Zhang J, Liu B, Li Z (2016) Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci Rep 6:36107PubMedPubMedCentral

30.

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Genin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, Andre F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15:1170–1178PubMed

31.

Flood B, Oficjalska K, Laukens D, Fay J, O'Grady A, Caiazza F, Heetun Z, Mills KH, Sheahan K, Ryan EJ, Doherty GA, Kay E, Creagh EM (2015) Altered expression of caspases-4 and -5 during inflammatory bowel disease and colorectal cancer: diagnostic and therapeutic potential. Clin Exp Immunol 181:39–50PubMedPubMedCentral

32.

Sun Y, Guo Y (2018) Expression of caspase-1 in breast cancer tissues and its effects on cell proliferation, apoptosis and invasion. Oncol Lett 15:6431–6435PubMedPubMedCentral

33.

Winter RN, Kramer A, Borkowski A, Kyprianou N (2001) Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res 61:1227–1232PubMed

34.

Biondo C, Mancuso G, Midiri A, Signorino G, Domina M, Lanza Cariccio V, Mohammadi N, Venza M, Venza I, Teti G, Beninati C (2014) The interleukin-1β/CXCL1/2/neutrophil axis mediates host protection against group B streptococcal infection. Infect Immun 82:4508–4517PubMedPubMedCentral

35.

Lee C-H, Syu S-H, Liu K-J, Chu P-Y, Yang W-C, Lin P, Shieh W-Y (2015) Interleukin-1 beta transactivates epidermal growth factor receptor via the CXCL1-CXCR2 axis in oral cancer. Oncotarget 6:38866–38880PubMedPubMedCentral

36.

Kubo A, Cook MB, Shaheen NJ, Vaughan TL, Whiteman DC, Murray L, Corley DA (2013) Sex-specific associations between body mass index, waist circumference and the risk of Barrett’s oesophagus: a pooled analysis from the international BEACON consortium. Gut 62:1684–1691PubMed

37.

Turati F, Tramacere I, La Vecchia C, Negri E (2013) A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol 24:609–617PubMed

38.

Picardo SL, O’Brien MP, Feighery R, O’Toole D, Ravi N, O’Farrell NJ, O’Sullivan JN, Reynolds JV (2015) A Barrett’s esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based registries and high risk of low grade dysplasia. Dis Esophagus 28:121–126PubMed

39.

Dinarello CA, Simon A, van der Meer JWM (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discovery 11:633–652PubMed

40.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131PubMed

41.

Borthwick LA (2016) The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Semin Immunopathol 38:517–534PubMedPubMedCentral

Titel: Characterizing caspase-1 involvement during esophageal disease progression
verfasst von: Gillian Barber
Akanksha Anand
Katarzyna Oficjalska
James J. Phelan
Aisling B. Heeran
Ewelina Flis
Niamh E. Clarke
Jenny A. Watson
Julia Strangmann
Brian Flood
Hazel O’Neill
Dermot O’Toole
Finbar MacCarthy
Narayanasamy Ravi
John V. Reynolds
Elaine W. Kay
Michael Quante
Jacintha O’Sullivan
Emma M. Creagh
Publikationsdatum: 01.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 12/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02650-4

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Characterizing caspase-1 involvement during esophageal disease progression

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer

Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy

Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model

Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer

Carrying the torch & facing new challenges

A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie